Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies999
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Apellis Pharmaceuticals
Apellis Pharmaceuticals develops therapeutics for chronic inflammatory lung diseases.
Sector
Subsector
Location
total rounds
total raised
Plexxikon
Plexxikon is a developer of small molecule pharmaceuticals.
Sector
Subsector
Location
total rounds
total raised
Mitochon Pharmaceuticals
Mitochon Pharmaceuticals is developing drugs targeting mitochondria for serious diseases with unmet medical needs.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 11.07.2024. Their latest round Post-IPO Equity
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Investments9
Sonoma BioTherapeutics
Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.
Sector
Subsector
Location
total rounds
total raised
Enlaza Therapeutics
Enlaza Therapeutics is a California-based biotechnology research company that is pioneering the field of covalent biologics.
Sector
Subsector
Location
total rounds
total raised
Sonoma BioTherapeutics
Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.
Sector
Subsector
Location
total rounds
total raised
Co-Investors
Investors2
Number of lead investors
Number of investors
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
U.S. Department of Health & Human Services
The U.S. Department of Health & Human Services promotes the health and well-being of Americans through effective health and human services.
Sector
Subsector
Location
count Of Investments
count Of Exists
Acquisitions2
Decibel Therapeutics acquired by Regeneron
acquirer
date
type
price
Decibel Therapeutics
Decibel Therapeutics is a biotechnology company developing treatments for hearing and balance disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
Checkmate Pharmaceuticals acquired by Regeneron
acquirer
date
type
price
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical-stage biopharmaceutical company that develops a new approach for cancer immunotherapy.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders3
Leonard S. Schleifer
Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. From 1984 to 1988 he was Assistant Professor at the Cornell University Medical College in the Departments of Neurology and Neurobiology. Leonard Schleifer received his M.D. and Ph.D. in Pharmacology from the University of Virginia. Leonard Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.
current job
organization founded
Leonard S. Schleifer
George D. Yancopoulos
George D. Yancopoulos, M.D., Ph.D., joined the Company in 1989 as its Founding Scientist and is currently President, Regeneron Laboratories and Chief Scientific Officer. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's three FDA-approved drugs - including EYLEA® (aflibercept) Injection, ZALTRAP Injection for Intravenous Infusion, and ARCALYST (rilonacept) Injection - as well as of its foundation technologies including the TRAP technology, VelociGene, and VelocImmune.
current job
organization founded
George D. Yancopoulos
Eric Shooter
Eric Shooter is a professor of neurobiology at the Stanford University School of Medicine. His research has dealt largely with understanding how nerves grow. He is perhaps best known discovering the protein known as nerve growth factor, which plays a key role in regrowing lost or damaged nerve cells. The discovery could someday make it possible to regrow nerves for those who have suffered spinal cord injuries, or to reverse the nerve degeneration that leads to Alzheimer's and Parkinson's diseases. Additionally, Shooter has researched the structure and mechanisms of neurotrophins, the proteins that keep nerve cells alive. He also discovered the gene in mice underlying a group of diseases called the demyelinating peripheral neuropathies in which the protective covering on nerves breaks down and the nerves are unable to function properly. The diseases are similar to human neurological diseases, and the discovery lays the groundwork for understanding how nerves repair themselves. Shooter obtained his PhD in chemistry in 1950 from the University of Cambridge and carried out his postdoctoral fellowship at the University of Wisconsin with J.W. Williams. Shooter was appointed as the USHS International Fellow with the Department of Biochemistry at Stanford in 1961. He was appointed associate professor of genetics and later as professor of biochemistry, and chaired the school's neurosciences PhD program. He served as chair of the Department of Neurobiology from 1975-87. Shooter has received numerous honors, including election to the Royal Society, London; Javits Neuroscience Investigator Award, NINDS; election to the American Academy of Arts and Sciences; the Ralph W. Garard Prize; Society of Neuroscience (shared with H. Thoenen) and was the Bristol-Myers Squibb Award winner for Distinguished Achievement in Neuroscience Research (shared with H. Thoenen).
current job
organization founded
Eric Shooter
Employee Profiles1217
Michael Burczynski
Senior Director, Precision Medicine
Vera Mastey
Vice president, health economics and outcomes research
Bryan Harper
Senior director, market access product and pipeline strategy
Sarah Drabick
Senior specialist, corporate communications
Vinay Desai
Senior director research and development it
Activity
Recent News43
The graph reveals the ratio (%) of positive news articles in a chosen time range